Market Research Reports, Inc. has announced the addition of “TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends” research report to their offering. See more at - http://mrr.cm/UD5

1. www.MarketResearchReports.com
: an industry
analysis of
technologies, pipelines,
stakeholders & deals an
industry analysis of
technologies,
stakeholders, deals &
trends
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.

2. www.MarketResearchReports.com
Introduction to Report
 Launch Date: May 20, 2018
 Number of Pages: 294
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 2,500
Price For Site User License: USD 5,000
Price For Global User License: USD 7,500
Delivery Time: Within 24 Hours (During Working
Days)

3. www.MarketResearchReports.com
About the Report
T-Cell Receptors (TCR) and Chimeric Antigen
Receptors (CAR) are the cutting edge of adoptive
T-cell therapy.
Both receptors deploy T-cells to target the tumor,
but CAR T-cells (CAR-T) are limited to binding to
cell surface antigens, while TCR T-cells (TCR-T)
recognize peptides (derived from intracellular
proteins) presented on the cell surface by the
major histocompatibility complex (MHC) class I.

4. www.MarketResearchReports.com
Key Highlights:
TCR-Ts have so far operated in the shadow of CAR-Ts,
but may have the advantage in solid tumors.
The first approved CD19-specific CAR-Ts are indicated
for hematologic malignancies, but CAR-Ts were less
successful against solid tumors.
This report „TCR Engineered T-Cell Therapy 2018: an
industry analysis of technologies, pipelines,
stakeholders & deals“ published in May 2018 brings you
up-to-date regarding key TCR-T players, key TCR-T
technologies and product candidates, business models,
deals and funding opportunities.
The report analyzes the TCR-T pipelines and
stakeholders in the field, especially focused and
diversified TCR-T companies and their relationship with
academia and major pharma/biotech.

5. www.MarketResearchReports.com
Key Highlights: Continues…
The report highlights the value of TCR-T assets in
terms of partnering economic conditions, acquisition
prices and financing rounds.
This report has been prepared by use of in-house
databases and desktop search to identify and describe
company, product, technology and business/financing
profiles which then were evaluated and analyzed with a
final outlook describing perspectives with challenges
and opportunities.
Sources of information are provided by scientific and
non-scientific references, e.g. press releases, stock
exchange disclosures, presentations, annual reports,
fact sheets and patent applications (with hyperlinks
leading to the source of information).

6. www.MarketResearchReports.com
Key questions answered:
Which targets are chosen for developmen of TCR-Ts?
How close are neoantigen-specific TCR-Ts to the
clinic?
Which technologies are used for generation of T-Cell
Receptors?
Has clinical proof-of-concept been shown for any TCR-
T?
How does the TCR-T pipeline look like?
What manufacturing strategies and solutions have
companies chosen?
Are next generation TCR-Ts already in development?
What are the key technologies for a successful TCR-T?
Who are the key players in the TCR-T field?

7. www.MarketResearchReports.com
Key questions answered: Continues…
How tough is competition among TCR-T developers?
Should companies be focused on TCR-Ts only or be
diversified into various adoptive T-cell therapeutics?
Which technologies and assets attract licensees?
How is the financing situation for TCR-T?
What are the key success factors for TCR-Ts?

8. www.MarketResearchReports.com
Target audience:
1. Leading Pharmaceutical companies
2. Suppliers
3. Contractors
4. Technologists
5. R&D staff
6. Consultants
7. Analyst
8. CSO's
9. CEO’s
10.CIO’s
11.COO’s

9. www.MarketResearchReports.com
Target audience: Continues…
12. Business development managers
13. Investors
14. Governments
15. Agencies
16. Industry organisations
17. Banks

10. www.MarketResearchReports.com
Report Coverage:
1. Executive Summary
2. Introduction, Overview & Background
3. Technologies
4. Pipeline
5. Manufacturing
6. Companies
7. Business Development & Financing
8. Outlook & Perspectives
9. References
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.

11. www.MarketResearchReports.com
Company Coverage: (Partial List)
1. Adaptimmune
2. Adicet Bio
3. Aeon Therapeutics Shanghai
4. AgenTus Therapeutics
5. Alpine Immune Science
6. Atreca
7. Bellicum Pharmaceuticals
8. BioNTech
9. Bluebird bio
10. Cell Medica
11. CRISPR Therapeutics
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.

12. www.MarketResearchReports.com
Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
For regular industry updates subscribe to our newsletter
at:
http://www.marketresearchreports.com/subscribe-to-
newsletter

13. www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/UD5
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Mr. Sudeep Chakravarty
Email : info@marketresearchreports.com
Phone: +1-302-703-9904 (USA) +91-8762746600 (India)